The introduction of denosumab, a fully human monoclonal antibody against Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), represented a significant advance in the treatment options for HD patients with osteoporosis. This evidence concerns the gene TNFSF11 and osteoporosis.